Abstract:BackgroundNewborn screening (NBS) is an important and successful public health program that helps improve the long-term clinical outcomes of newborns by providing early diagnosis and treatment of certain inborn diseases. The development of next-generation sequencing (NGS) technology provides new opportunities to expand current newborn screening methodologies.MethodsWe designed a a newborn genetic screening (NBGS) panel targeting 135 genes associated with 75 inborn disorders by multiplex PCR combined with NGS. With this panel, a large-scale, multicenter, prospective multidisease analysis was conducted on dried blood spot (DBS) profiles from 21,442 neonates nationwide.ResultsWe presented the positive detection rate and carrier frequency of diseases and related variants in different regions; and 168 (0.78%) positive cases were detected. Glucose-6-Phosphate Dehydrogenase deficiency (G6PDD) and phenylketonuria (PKU) had higher prevalence rates, which were significantly different in different regions. The positive detection of G6PD variants was quite common in south China, whereas PAH variants were most commonly identified in north China. In addition, NBGS identified 3 cases with DUOX2 variants and one with SLC25A13 variants, which were normal in conventional NBS, but were confirmed later as abnormal in repeated biochemical testing after recall. Eighty percent of high-frequency gene carriers and 60% of high-frequency variant carriers had obvious regional differences. On the premise that there was no significant difference in birth weight and gestational age, the biochemical indicators of SLC22A5 c.1400C > G and ACADSB c.1165A > G carriers were significantly different from those of non-carriers.ConclusionsWe demonstrated that NBGS is an effective strategy to identify neonates affected with treatable diseases as a supplement to current NBS methods. Our data also showed that the prevalence of diseases has significant regional characteristics, which provides a theoretical basis for screening diseases in different regions.

Current Problems and Prospect on Tandem Mass Spectrometry Based Newborn Inherited Metabolic Diseases Screening

Problems and reflection on the screening and diagnosis for disease of newborn

[Screening for neonatal inborn errors of metabolism by electrospray ionization-tandem mass spectrometry and follow-up].

Preliminary Application of Region 4 Stork Project Used in Newborn Screening by Tandem Mass Spectrometry

A Multi-Center Study of Biochemical and Hotspot Gene Screening for Neonatal Genetic Metabolic Diseases

Application of a Next-Generation Sequencing (NGS) Panel in Newborn Screening Efficiently Identifies Inborn Disorders of Neonates

A Multicenter Prospective Study of Next-Generation Sequencing-Based Newborn Screening for Monogenic Genetic Diseases in China

Integration of Machine Learning Techniques as Auxiliary Diagnosis of Inherited Metabolic Disorders - Promising Experience with Newborn Screening Data.

Newborn Screening for Inherited Metabolic Diseases Using Tandem Mass Spectrometry in China: Outcome and Cost-Utility Analysis

Reference Standards for Newborn Screening of Metabolic Disorders by Tandem Mass Spectrometry: A Nationwide Study on Millions of Chinese Neonatal Populations

Neonatal screening for congenital hypothyroidism and phenylketonuria in China

Application of Region 4 Stork system in the neonatal screening for very long chain acyl-CoA dehydrogenase deficiency by tandem mass spectrometry

[Retrospective Study on Neonatal Screening for Congenital Hypothyroidism and Phenylketonuria in China in the Past 22 Years].

Newborn Screening in Zhejiang, China

Screening for Inborn Errors of Metabolism in High-Risk Children: a 3-Year Pilot Study in Zhejiang Province, China

Screening of 1.17 million newborns for inborn errors of metabolism using tandem mass spectrometry in Shanghai, China: A 19-year report

Newborn Screening for Inborn Errors of Metabolism by Next-Generation Sequencing Combined with Tandem Mass Spectrometry

The significance of machine learning in neonatal screening for inherited metabolic diseases

Analysis of Imprecision for Internal Quality Control of Newborn Screening by Tandem Mass Spectrometry in China, 2015 - 2021

Harmonization of distributed multi‐center analysis based on dried blood spot reference materials supporting the screening of neonatal inherited metabolic disorders

The screening of inborn errors of metabolism in sick Chinese infants by tandem mass spectrometry and gas chromatography/mass spectrometry.